+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Field study on the decrease of lipids using etofibrate

Fortschritte der Medizin 94(13): 785-790

Field study on the decrease of lipids using etofibrate

A field-trial on Etofibrat was performed on 4405 patients suffering from primary and secondary hyperlipoproteinemia. The results were proved statistically. After a 3 to 4 weeks treatment the concentration of cholesterol as well as tryglicerides in the serum decreased significantly. After 6 to 8 weeks treatment the lipid-lowering effect was even stronger. Nearly 90% of the patients investigated gave a positive response to the treatment. Part of the population had undergone a treatment with other lipid-lowering agents before-most likely without sufficient success-in these cases a further lipid-lowering effect due to Etofibrat could be shown. Under-dosage in premedication cannot be excluded. The stratification of the patients in different groups of diagnosis showed a nearly similarity of both blood lipids independent of the diagnosis. This could also be confirmed for the group of patients suffering from diabetes. To prove the lipid-lowering efficacy of Etofibrat a population was withdrawn from treatment. Cholesterol as well as tryglicerides increased significantly during the interval without treatment. During a long-term study both lipid fractions could be kept down without increasing of the daily Etofibrat dose. The tolerance of Etofibrat was stated to be good up to very good. Objectively the measured enzymes SGOT, SGPT and gamma-GT showed a decrease of the means. Subjectively the occurrence of an often intermediate heat sensation and/or rubedo was of relevance. The low daily dose compared with other lipid-lowering agents gives indication for a better pharmacocinetic behaviour of the drug;

(PDF 0-2 workdays service: $29.90)

Accession: 038940229

PMID: 8362

Related references

Lowering lipids rapidly and permanently with etofibrate. Medizinische Klinik 77(3): 35-38, 1982

Biliary and plasma lipids and lipid lowering chemo therapy studies with clofibrate fenofibrate and etofibrate in healthy volunteers. Atherosclerosis 36(3): 323-330, 1980

Studies with etofibrate in the rat: Part II. A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis. Biochimica et Biophysica Acta 1168(3): 340-347, 1993

Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. European Journal of Drug Metabolism and Pharmacokinetics 20(2): 113-118, 1995

Action of etofibrate, clofibrate and nicotinic acid on the metabolism of lipids in normolipemic rats. Short term effects and method of action. Archivos de Farmacologia Y Toxicologia 5(1): 29-42, 1979

Tetraether type polar lipids increase after logarithmic growth phase of Methanobacterium thermoautotrophicum in compensation for the decrease of diether lipids. FEMS (Federation of European Microbiological Societies) Microbiology Letters 109(2-3): 283-288, 1993

Etofibrate and clofibrate in double-blind study. Deutsche Medizinische Wochenschrift 101(42): 1545-1545, 1976

Changes in fatty acids constituting lipids in fish muscle during storage at low temperature (5 deg C) - decrease rate of C22:6 acid as a criterion for the oxidative deterioration of lipids.. Bulletin of the Japanese Society of Scientific Fisheries 37(9): 912-918, 1971

Changes in fatty acids constituting lipids in fish muscle during storage at low temperature (SEGC) - Decrease rate of C :6acid as a criterion for the oxidative deterioration of lipids. BullSoc. scient. Fish: 912-918, 1971

Study of the antilipemic effect of etofibrate (Lipo-Merz). Polski Tygodnik Lekarski 38(17): 529-532, 1983